Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate database

View Full Paper
Ask AI
Bookmark
Share

Authors

HCHetty E. CarrawayBRBenjamin RollesAHAmyah Harris

Discussion

Loading...

Member takes

Overview

Analysis reveals higher complete remission rates with HMA plus venetoclax in HR-MDS, suggesting benefits in certain patients.

Key Points

  • The study aims to compare outcomes of higher-risk myelodysplastic syndromes treated with hypomethylating agents versus a combination with venetoclax.
  • Utilized the icMDS VALIDATE database with over 4000 MDS patients.
  • Compared response rates of patients treated with HMAm or HMA/VEN as frontline therapy.
  • Analyzed overall survival using Kaplan-Meier methods, and applied Cox and logistic regression models for adjustments.
  • 1907 patients included in the analysis with varying treatment regimens.
  • HMA/VEN led to higher composite complete remission rates compared to HMAm (48.8% vs. 27.7%).
  • Median overall survival did not differ significantly between the treatment groups (19.6 months for HMA/VEN vs. 17.4 months for HMAm).

Cite This Study

Carraway et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dd81https://doi.org/10.1182/blood-2025-606
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax—an analysis from the International Consortium for MDS (icMDS) VALIDATE database2026 · 2 citations
  2. 2Hypomethylating agent with venetoclax versus hypomethylating agent alone in frontline management of myelodysplastic syndrome - impact of subgroups on clinical outcomes2025
  3. 3The role of hypomethylating agents and venetoclax combination in higher risk myelodysplastic syndromes2025
  4. 4Venetoclax in combination with hypomethylating agents shows promising activity in Acute Myeloid Leukemia with late relapse post allogeneic stem cell transplant: From the EBMT acute leukemia working party2025
  5. 5A real-world experience of venetoclax combined with hypomethylating agents vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia patients2024 · 2 citations